CD28 Antibody, anti-human, REAlease®
Synonyms: T44, Tp44
RECOMBINANT EXTENDED VALIDATION
Clone:
REAL105
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD28 Antibody, anti-human, REAlease®

Flow cytometry applications
APC
FITC
PE
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-112-096, 130-112-263, 130-122-662
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD28-APC (B) or with the corresponding REAL Control (A). REAlease CD28-APC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD28-APC (D). Cells were labeled with CD3 antibodies in addition and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Application imageView details view details

Application imageView details view details

Application imageView details view details

Application imageView details view details
Extended validation for CD28 Antibody, anti-human, REAlease®
Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD28. Human peripheral blood mononuclear cells (PBMCs) were stained with CD28 antibodies and with a suitable counterstaining. As a control, CD28 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD28 (REAL105). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD28 Antibody, anti-human, REAlease®
Overview

Clone REAL105 is an antibody fragment derived from the full CD28 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL105 recognizes the human CD28 antigen, a type I transmembrane protein, which is highly expressed on CD3+ thymocytes, most peripheral thymocytes, and plasma cells but not in less mature B cells. Binding of CD28 to its ligands CD80 or CD86 costimulates T cell effector function and T cell–dependent antibody production in vitro and in vivo. In the presence of antibodies directed against CD2 and CD3, CD28 antibodies stimulate T cell proliferation and cytokine production.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

T44, Tp44

Detailed product information

Technical specifications

Clone
REAL105
Clonality
monoclonal
Isotype control
Control Antibody
Host
cell line
Type of antibody
Releasable antibodies, Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD28
Distribution of antigen
thymocytes, plasma cells
RRID
AB_2784109, AB_2751071, AB_2751095, AB_2751456, AB_2784110, AB_2751102, AB_2751444, AB_2784111, AB_2751083
Resources for CD28 Antibody, anti-human, REAlease®
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD28 Antibody, anti-human, REAlease®
Publications
  1. June, C. H. et al. (1990) Role of the CD28 receptor in T-cell activation. Immunol. Today 11 (6): 211-216
  2. Krummel, M. F. and Allison, J. P. (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (2): 459-465
  3. Linsley, P. S. et al. (1993) The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11: 191-212
  4. Bahlis, N. J. et al. (2007) CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 109 (11): 5002-5010
  5. Kozbor D. J. et al. (1987) Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J Immunol 138 (12): 4128-4132
  6. Freeman, G. J. et al. (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262 (5135): 909-911

You have previously chosen International as your location.
What do you want to do?